This supports the notion that BRAF activation compensates for lack of TK mutation in GIST but does not seem to play a relevant role in secondary resistance, where KIT exon 13 and exon 17 mutations seem to be prevalent, in line with published data [16]. The gene discussed is TKT; the disease is gastrointestinal stromal tumor.